Engagement Code: APEX-2026-01
Client: Apollo Hospitals Enterprise Ltd (NSE: APOLLOHOSP)
Sponsor: Board of Directors | Chairman's Office
Scope: 6-week engagement | April 2026
Methodology: Hypothesis-driven MBB methodology (SCQA → Issue Tree → Recommendation)
Apollo trades at 58–71x P/E on the back of 5 consecutive quarters of PAT growth (+35% YoY, FY26). It is executing an ₹8,300 Cr bed expansion adding 4,400 beds by FY30 — while simultaneously running Apollo 24|7 (₹1,000+ Cr cumulative burn, break-even imminent) and preparing to demerge HealthCo (estimated ₹25,000–35,000 Cr unlock).
The capital allocation trilemma: Apollo cannot simultaneously maximise (a) growth capex, (b) digital investment, and (c) shareholder returns. Something must give — and the market is paying for execution certainty, not optionality.
An original analytical construct developed for this engagement:
GROWTH CAPEX
(₹8,300 Cr beds)
/\
/ \
/ ZONE\
/ OF \
/ TENSION \
/ • Apollo \
/ today \
/________________\
DIGITAL & SHAREHOLDER
OPTIONALITY RETURNS
(24|7, HealthCo) (Div + Buyback)
The law of the trilemma: At any ROIC-to-WACC spread, a company can lean toward two vertices credibly. The recommended path (Disciplined Compounder) positions Apollo at Growth + Returns, using the HealthCo demerger to harvest digital optionality without burning shareholder cash.
| File | Type | Pages | Description |
|---|---|---|---|
apollo-hospitals-full-engagement-deliverable.pdf |
Full engagement | 10 | Complete MBB-style output: Engagement Frame → Diagnostic → Capital Allocation → Quantified Scenarios → Recommendation → Risk/Governance → Narrative |
apollo-hospitals-board-strategy-case.pdf |
Board deck | 6 | Condensed strategy case for board presentation |
apollo-247-unit-economics-teardown.pdf |
Workstream | 8 | Deep dive: path from ₹29 Cr loss to ₹100 Cr EBITDA, CAC story, cohort retention, gate design |
apollo-247-ceo-brief-APEX-2026-01.pdf |
CEO memo | 3 | Two-page decision brief for Executive Vice Chairperson |
apollo-apex-capital-allocation-model.xlsx |
Financial model | — | APEX Capital Allocation Waterfall: SOTP valuation, 3-scenario analysis, sensitivity tables |
Adopt the APEX Capital Allocation Waterfall — every rupee of FY27–FY30 FCF (~₹14,000 Cr) allocated in priority order:
| # | Bucket | Allocation | Guardrail |
|---|---|---|---|
| 1 | Maintenance capex + WC | ₹3,200 Cr | Non-negotiable |
| 2 | Committed bed expansion | ₹5,000 Cr | Cost overrun cap 8% |
| 3 | Apollo 24|7 burn | ≤₹450 Cr | Hard gate: break-even Q2 FY27 |
| 4 | HealthCo demerger | ₹200 Cr | Close by Q3 FY27 |
| 5 | Shareholder returns | 25–30% residual FCF | ₹25/sh dividend floor |
| 6 | Brownfield M&A | ₹800 Cr | 18% IRR hurdle |
Projected TSR CAGR: 17% vs 8–10% for alternatives. Implied FY30 mcap: ₹1.7 L Cr.
- 3-path scenario analysis (Accelerate / Disciplined Compounder / Return Capital) with full FY30 financials
- SOTP valuation — base case equity value ₹9,760/share (~32% upside vs ₹7,400)
- Sensitivity table — 70% of valuation in two variables: hospital margin trajectory and HealthCo multiple
- Apollo 24|7 unit economics — CAC ₹360 → ₹95 (73% decline); LTV/CAC <1x → 9x; payback 240 → 27 months
- 2-of-3 gate design — contribution margin/user, quarterly EBITDA, private label mix
- Monte Carlo-informed risk register — 7 risks with P50 EBITDA impacts and pre-committed responses
Hypothesis-driven problem structuring · SCQA pyramid · Issue tree with kill criteria · Capital allocation strategy · SOTP valuation · Unit economics reverse-engineering · Scenario modelling · Sensitivity analysis · Board-level communication · CEO decision memo
Prepared under hypothesis-driven MBB methodology. All figures triangulated from Q3 FY26 results, management guidance, and 26-analyst consensus (avg TP ₹8,770). Data provenance tagged [D/T/A] throughout.